Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the unusual humidity descending upon the otherwise comfortable Pharmalot campus. Our official mascot is snoozing nearby and we have yet another cup of stimulation at hand. Our choice today is Jack Daniels (yes, this is a real one, folks). Meanwhile, there is much to do. So here is the latest menu of tidbits for you to peruse. Hope you conquer the world today and, as always, please keep in touch …

President Trump said the Department of Veterans Affairs will buy “a lot” of the controversial new Spravato antidepressant to help fight veteran suicides, The Military Times writes. Earlier this year, Trump reportedly pushed the VA to quickly adopt the ketamine-like drug from Johnson & Johnson (JNJ) despite concerns from some medical experts about its effectiveness. In June, a VA medical advisory panel declined to put the drug on its formulary, but did not ban it altogether. Instead, VA doctors must provide added justification for patient use.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.